Kidney Transplants: Are We Measuring Kidney Function the Right Way?
"A new look at how creatinine and cystatin C levels impact early detection of kidney problems after transplantation."
Kidney transplantation is a life-changing treatment for end-stage renal disease, improving both the quality and length of life for many patients. The success of a kidney transplant relies heavily on the ability to monitor the health and function of the new kidney. Doctors keep a close eye on how well the kidney is filtering waste, a process known as the glomerular filtration rate (GFR). Spotting any decline in kidney function early is crucial for taking steps to protect the new organ and ensure the transplant continues to be successful.
Traditionally, doctors have used measurements of serum creatinine (sCr) to assess kidney function. While sCr is a standard marker, it has limitations. Factors like muscle mass, diet, and even a person's sex can influence sCr levels, making it difficult to get a clear picture of kidney health. Recently, cystatin C (CyC) has emerged as another important marker. Unlike creatinine, cystatin C is less affected by muscle mass and other factors, offering a potentially more accurate way to assess GFR.
A recent study published in the Journal of the Korean Surgical Society compared the effectiveness of cystatin C and serum creatinine in monitoring kidney function in renal transplant recipients. This research provides valuable insights into which marker might be better for the early detection of declining kidney function, ultimately helping doctors provide the best possible care for their patients. Let's delve into the details of this study and explore what it means for the future of kidney transplant monitoring.
The Current Transplant Landscape
The OPTN/SRTR 2024 Annual Data Report: Kidney provides a comprehensive overview of kidney transplantation in the United States, including adult and pediatric waiting lists, deceased and living donation, transplant procedures, and outcomes. HRSA's Data Reports platform allows users to examine the latest U.S. organ donation and transplantation data through customizable criteria. The Annual Data Report, developed by SRTR and the Organ Procurement and Transplantation Network, also includes chapters covering other organs, deceased donation, and special topics.
Creatinine-Based Assessment
Kidney transplant recipients are commonly monitored with serum creatinine and estimated GFR, but measurement methods can affect interpretation. Differences between the Jaffe and enzymatic serum-creatinine methods can affect chronic kidney disease detection and staging in kidney transplant recipients. Serum creatinine measurement itself has recognized method limitations, while proposed transplant-specific equations have been evaluated with variable GFR and creatinine measurement methods and limited representation of non-White participants.
From Impossible to Routine
Human kidney transplantation was initially viewed as impossible but ultimately developed into a routine, life-saving therapy. Its progress has depended on multidisciplinary science and on the distinctive relationship between donors and recipients. Timelines such as the Medical University of South Carolina's A Timeline of Kidney Transplantation document significant firsts and developments in the field.
Cystatin C vs. Creatinine: Which Marker Provides a Clearer Picture?
The study, led by Young Jae Jung and colleagues at Hanyang University College of Medicine in Seoul, Korea, aimed to determine whether cystatin C (CyC) or serum creatinine (sCr) is more effective in assessing renal function in kidney transplant recipients. The researchers analyzed data from 72 adult patients who had undergone renal transplantation between 2001 and 2008. They compared the accuracy, bias, precision, and sensitivity of both markers in relation to 24-hour urine creatinine clearance (CrCl), a standard measure of kidney function.
- Accuracy: Cr-GFR estimates were more accurate than CyC-GFR estimates overall.
- Bias: Both Cr-GFR and CyC-GFR showed biases, with Cr-GFR overestimating kidney function at lower CrCl levels and underestimating it at higher levels.
- Sensitivity: CyC was found to be more sensitive in detecting low GFR, particularly when GFR was below 60 mL/min/1.73 m².
Cystatin C and Combined Estimates
Recent research is examining whether cystatin C can improve kidney-function estimation for transplant recipients. Cystatin C has less dependence on muscle mass than creatinine, although specific guidance for kidney transplant recipients remains limited despite support for its use in chronic kidney disease in the 2024 KDIGO guidelines. A systematic review and meta-analysis reported that equations combining creatinine and cystatin C provided more balanced estimates overall, while differences in study methods and transplant-related factors could affect individual results.
When Creatinine Misleads
Serum creatinine is useful for monitoring but can be difficult to interpret in individual transplant cases. One report described a 42-year-old man whose creatinine rose to 6.07 mg/dL from a baseline of 2.0 mg/dL six months after a deceased-donor transplant, despite no symptoms, no previous rejection symptoms, and adherence to immunosuppression. Other research has used longitudinal creatinine measurements and time-to-event modeling to study graft failure while accounting for outlying creatinine values, and a 2026 study reported that the prognostic value of early post-transplant creatinine remains insufficiently established in modern high-risk cohorts.
Measuring Versus Estimating GFR
Kidney function is crucial in caring for transplant recipients and in designing and interpreting transplantation trials. It is most commonly assessed with serum creatinine or an estimated GFR based on serum creatinine, although directly measured GFR provides a comparison standard. In a 2024 study of pediatric kidney transplant recipients, researchers compared creatinine- and cystatin C-based equations with measured GFR using iohexol to evaluate which estimates more closely reflected measured function.
The Future of Kidney Transplant Monitoring
The study underscores the importance of using a combination of markers and careful monitoring to assess kidney function in transplant recipients. While creatinine remains a valuable tool, cystatin C offers an additional layer of insight, particularly for early detection of declining kidney function. As research continues, refining GFR formulas and incorporating new biomarkers may further improve our ability to protect transplanted kidneys and ensure long-term success for patients.
The Case for Better Precision
Accurate GFR estimation is essential for monitoring long-term graft function after kidney transplantation. Serum creatinine remains the primary biomarker recommended for estimating GFR in kidney transplant recipients, but its accuracy may be reduced in people with low muscle mass. Current review evidence indicates that combining creatinine with cystatin C may provide more balanced estimates overall, although transplant-related factors can influence individual results.
Toward More Individualized Monitoring
Future kidney-transplant monitoring may move toward more individualized assessments rather than relying on a single kidney-function measure. Possible directions include combining complementary biomarkers, confirming uncertain results with direct measurement, and interpreting changes alongside patient-specific factors such as muscle mass and treatment context. These approaches remain an evolving prospect, and their practical role will depend on further validation in transplant recipients.
Why Creatinine Can Rise
A rise in creatinine after kidney transplantation can have multiple explanations. Reported possibilities range from reversible changes in fluid volume to acute rejection and longer-term medication side effects. This range means that an elevated creatinine result is an important signal that requires clinical interpretation rather than a complete explanation by itself.
Supplements and Misleading Signals
Creatine supplementation can complicate interpretation of kidney-related laboratory results in transplant recipients. A pilot case study reported no adverse impact on kidney function after six weeks of 5 g/day creatine monohydrate, as indicated by CKD-EPI eGFRcr-cys, and found that increased urine creatinine did not correlate with serum kidney-function tests. Separately, a case report described elevated serum creatinine in a renal-transplant recipient taking creatine ethyl ester, but not creatine monohydrate, illustrating why supplement use should be included when interpreting test results.